首頁 > 市場調查報告書 > 製藥

癌症呼吸器

肺癌藥物市場規模、佔有率和成長分析（治療方法、癌症類型、分子類型、通路和地區分類）—2026-2033年產業預測

市場調查報告書

商品編碼

1900379

肺癌藥物市場規模、佔有率和成長分析（治療方法、癌症類型、分子類型、通路和地區分類）—2026-2033年產業預測

Lung Cancer Therapeutics Market Size, Share, and Growth Analysis, By Therapy (Radiation Therapy, Targeted Therapy), By Cancer Type, By Type of Molecule, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月22日 | 出版商:

SkyQuest | 英文 242 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球肺癌藥物市場預計到 2024 年將達到 364 億美元，到 2025 年將達到 412 億美元，到 2033 年將達到 1,111 億美元，預測期（2026-2033 年）的複合年成長率為 13.2%。

肺癌治療市場正經歷顯著成長，這主要得益於診斷技術的進步、創新治療方法的湧現以及全球對肺癌意識的不斷提高。政府加大對醫療基礎設施和高品質治療方案的投入是推動市場擴張的關鍵因素。此外，人們對多樣化治療方法的認知不斷提高也進一步刺激了市場需求。同時，可支配收入的增加、新技術研發的持續推進、先進放射線治療的應用以及開發中國家的經濟成長等因素也推動了市場前景。主要企業正致力於創新並強化產品系列，以改善患者的治療效果。鑑於肺癌的高發病率和高死亡率，它仍然是醫療保健領域持續推進治療研發的重點領域。

推動全球肺癌藥物市場發展的因素

全球肺癌發生率的不斷上升對全球肺癌治療市場產生了重大影響。導致這一激增的主要因素包括吸煙、環境污染和生活方式的改變，這些因素共同造成了確診病例的顯著增加。這種成長推動了對有效治療方案和旨在改善患者照護的創新治療方法的需求不斷成長。隨著醫療系統和研究人員應對這一日益嚴峻的挑戰，對先進治療方案的需求也在不斷演變，從而推動了肺癌治療市場的發展。

全球肺癌藥物市場面臨的限制因素

全球肺癌治療市場面臨嚴峻挑戰，主要原因是新治療方法的核准受到嚴格監管要求的限制。這項嚴苛且往往耗時的流程可能會延遲患者獲得創新治療方法的機會，並阻礙疾病管理的及時介入。此外，此類限制性法規可能抑制研發投入，從而限制新治療方法進入市場。因此，這些障礙不僅減緩了肺癌治療方法的進展，也阻礙了醫療專業人員為與這種致命疾病作鬥爭的患者提供最佳護理的努力。

全球肺癌藥物市場趨勢

全球肺癌治療市場正經歷著向個人化醫療的重大轉變，其特點是將基因譜分析和生物標記整合到治療方案設計中。這種變革性的方法針對每位患者癌症的獨特特徵，在提高治療效果的同時，最大限度地減少副作用。因此，對針對個別患者特徵量身定做的標靶治療和免疫療法的需求日益成長。這一趨勢不僅代表著治療模式的根本性轉變，也凸顯了持續進行研究和技術進步以最佳化肺癌治療患者療效的必要性。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

F. Hoffmann-La Roche Ltd（Switzerland）
Pfizer Inc.（US）
Novartis AG（Switzerland）
AstraZeneca PLC（UK）
Merck & Co. Inc.（US）
Eli Lilly and Company（US）
Bristol Myers Squibb Company（US）
Boehringer Ingelheim International GmbH（Germany）
Johnson & Johnson（US）
Amgen Inc.（US）
Teva Pharmaceutical Industries Ltd.（Israel）
AbbVie Inc.（US）
GlaxoSmithKline plc（GSK）（UK）
Sun Pharmaceutical Industries Ltd.（India）
Takeda Pharmaceutical Company Limited（Japan）
Bayer AG（Germany）
Dr. Reddy's Laboratories（India）

結論與建議

簡介目錄

Product Code: SQMIG35J2088

Global Lung Cancer Therapeutics Market size was valued at USD 36.4 Billion in 2024 and is poised to grow from USD 41.2 Billion in 2025 to USD 111.1 Billion by 2033, growing at a CAGR of 13.2% during the forecast period (2026-2033).

The lung cancer therapeutics market is seeing notable growth, fueled by advancements in diagnostic techniques, innovative treatments, and rising awareness surrounding lung cancer globally. Enhanced government investments in healthcare infrastructure and quality treatment options are critical drivers of this market's expansion. As individuals increasingly recognize the diverse treatment avenues available, market demand intensifies. Furthermore, factors such as rising disposable income, continuous R&D for new technologies, the adoption of advanced radiation therapy, and economic growth in developing nations bolster market prospects. Key players are focusing on innovation and enhancing their product portfolios to improve patient outcomes. Given its high prevalence and significant mortality rate, lung cancer remains a critical area of focus for continued therapeutic advancements in the healthcare sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lung Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Lung Cancer Therapeutics Market Segments Analysis

Global Lung Cancer Therapeutics Market is segmented by Therapy, Cancer Type, Type of Molecule, Distribution Channel, Drug Class, End User and region. Based on Therapy, the market is segmented into Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Others. Based on Cancer Type, the market is segmented into Non-small cell lung cancer (NSCLC) and Small cell lung cancer (SCLC). Based on Type of Molecule, the market is segmented into Small molecules and Biologics. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on Drug Class, the market is segmented into Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Lung Cancer Therapeutics Market

The rising incidence of lung cancer worldwide significantly influences the global lung cancer therapeutics market. Key contributors to this surge include tobacco use, environmental pollution, and changes in lifestyle, all of which have led to a notable increase in diagnosed cases. This escalation is fostering a heightened demand for effective treatment options and innovative therapies aimed at enhancing patient care. As healthcare systems and researchers strive to address this growing challenge, the need for advanced therapeutic solutions continues to evolve, driving progress within the market dedicated to combating lung cancer.

Restraints in the Global Lung Cancer Therapeutics Market

The Global Lung Cancer Therapeutics market faces significant challenges due to stringent regulatory requirements that govern the approval of new therapies. This rigorous and often lengthy process can delay patient access to innovative treatments, hindering timely intervention in managing the disease. Moreover, such restrictive regulations can deter investment in research and development, limiting the flow of new therapies into the market. As a result, these barriers not only slow down advancements in lung cancer treatment options but also create obstacles for healthcare professionals striving to provide the best care for patients battling this serious illness.

Market Trends of the Global Lung Cancer Therapeutics Market

The global lung cancer therapeutics market is witnessing a significant shift towards personalized medicine, characterized by the integration of genetic profiling and biomarkers in treatment design. This transformative approach enhances the effectiveness of therapies while minimizing adverse effects, thereby addressing the unique characteristics of each patient's cancer. As a result, there is a growing demand for targeted therapies and immunotherapies that are specifically aligned with individualized patient profiles. This trend not only represents a fundamental change in the treatment paradigm but also emphasizes the need for ongoing advancements in research and technology to optimize patient outcomes in lung cancer care.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Lung Cancer Therapeutics Market Size by Therapy & CAGR (2026-2033)

Market Overview
Radiation Therapy
- External Beam
- Internal Beam
- Systemic
Targeted Therapy
- Bevacizumab
- Dabrafenib/Trametinib
- Erlotinib Hydrochloride
- Osimertinib
- Others
Immunotherapy
- Durvalumab
- Nivolumab
- Atezolizumab
- Pembrolizumab
Chemotherapy
Others

Global Lung Cancer Therapeutics Market Size by Cancer Type & CAGR (2026-2033)

Market Overview
Non-small cell lung cancer (NSCLC)
Small cell lung cancer (SCLC)

Global Lung Cancer Therapeutics Market Size by Type of Molecule & CAGR (2026-2033)

Market Overview
Small molecules
Biologics

Global Lung Cancer Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Global Lung Cancer Therapeutics Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Alkylating Agents
Antimetabolites
EGFR Inhibitors
Mitotic Inhibitors
Multikinase Inhibitors
Others

Global Lung Cancer Therapeutics Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Specialty Clinics
Homecare
Others

Global Lung Cancer Therapeutics Market Size & CAGR (2026-2033)

North America (Therapy, Cancer Type, Type of Molecule, Distribution Channel, Drug Class, End User)
- US
- Canada
Europe (Therapy, Cancer Type, Type of Molecule, Distribution Channel, Drug Class, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Therapy, Cancer Type, Type of Molecule, Distribution Channel, Drug Class, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Therapy, Cancer Type, Type of Molecule, Distribution Channel, Drug Class, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Therapy, Cancer Type, Type of Molecule, Distribution Channel, Drug Class, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co. Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb Company (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (GSK) (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments